How Will the HFrEF Therapy Landscape Change?
Thursday, December 3rd: 1:30 – 3:00 pm
Heart failure (HF) remains one of our most challenging CV diseases, to diagnose, to treat, and to understand. This is due in part to the fact that HF is not just one disease. Will we refine our diagnoses by phenotype and find targeted therapies? Over the next few years, how will the therapy landscape change for trialists, clinicians, and their patients?
This session is chaired by Prof. Tiny Jaarsma the Editor-in-Chief of the European Journal of Cardiovascular Nursing and a researcher from Linkoping University in Linkoping, Sweden, and the legendary Prof. Faiez Zannad of the Université de Lorraine and Inserm Clinical Investigation Center at Institut Lorrain du Coeur et des Vaisseaux in Nancy, France.
This session will look at the mechanisms of heart failure and its treatments and debate the issue personalized medicine in CV diseases. Safety and cost issues, particularly important because of the frequent need for polypharmacy to manage HF, will be discussed. Moving beyond the western world, this session will tackle globalization issues including implementation of trials and guideline recommended treatments in low- and middle-income countries. Finally, Tiny Jaarsma, will convince you that EVERY HF patient should enroll in a multidisciplinary HF disease management program. These programs have been shown to be effective in decreasing rehospitalisation and mortality, improving quality of life, and are guideline recommended standard of care. How can you refuse?
Other speakers include Subodh Verma (Toronto, Canada), John Cleland (Glasgow, Scotland), and Salim Yusuf (Hamilton, Canada). Come further explore the future of HF management during the moderated, multi-stakeholder, expert panel debate.